3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
80
Neoplasms
14
Neoplasm Metastasis
14
Brain Neoplasms
9
Breast Neoplasms, Male
7
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Stomach Neoplasms
4
Urinary Bladder Neoplasms
3
Salivary Gland Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Inflammatory Breast Neoplasms
3
Gallbladder Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Squamous Cell
3
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Bile Duct Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thymoma
1
Spinal Cord Neoplasms
1
Interventions
Oxaliplatin
10
Capecitabine
9
Cisplatin
8
Fluorouracil
5
Leucovorin
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
atezolizumab
3
Nivolumab
3
trebananib
2
ponatinib
2
pembrolizumab
2
avelumab
2
apatinib
2
alectinib
2
XELOX
2
Standard of Care
2
S 1 (combination)
2
Radiotherapy
2
Radiosurgery
2
Ocoxin
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
Folfox protocol
2
Everolimus
2
Erlotinib Hydrochloride
2
Acupuncture Therapy
2
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Neoplasms
×
Lapatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled